SPTX

Seaport Therapeutics Inc

21.36

Jul 01 • 12:40PM ET -0.36 (-1.66%)

Healthcare Biotechnology USA Small NASD

Peers: AVLN ABCL ABSI ABEO AAPG ACAD ABVX ARWR ABOS ARQT

| Held by: SCHA SBIO VTI VXF SCHB VTWO WCEO VTWG VTWV VTHR

Scroll to Statements

Index	-
Market Cap	1.14B
Enterprise Value	1.29B
Income	-
Sales	-
Book/sh	-2.16
Cash/sh	3.41
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	54
IPO	May 01, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	6.26
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	13.24
Current Ratio	13.24
Debt/Eq	0.03
LT Debt/Eq	0.02
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-2.44
EPS next Q	-0.57
EPS this Y	78.13%
EPS next Y	64.63%
EPS next 5Y	56.70%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Jun 08 BMO
EPS/Sales Surpr.	-93.78% -

Insider Own	67.29%
Insider Trans	3.19%
Inst Own	5.22%
Inst Trans	15.89%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	14.97%
SMA50	20.79%
SMA200	20.79%
Trades

Shs Outstand	53.53M
Shs Float	17.51M
Short Float	11.07%
Short Ratio	4.76
Short Interest	1.94M
52W High	23.00 -7.14%
52W Low	14.85 43.83%
Volatility	8.65% 8.50%
ATR (14)	1.47
RSI (14)	61.83
Beta	-
Rel Volume	0.17
Avg Volume	407.65K
Volume	36,519

Perf Week	10.61%
Perf Month	24.68%
Perf Quarter	-
Perf Half Y	-
Perf YTD	7.65%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	35.00
Prev Close	21.72
Price	21.36
Change	-1.66%

Date	Action	Analyst	Rating Change	Price Target Change
May-26-26	Initiated	Stifel	Buy	$30
May-26-26	Initiated	Leerink Partners	Outperform	$35
May-26-26	Initiated	JP Morgan	Overweight	$42
May-26-26	Initiated	Citigroup	Buy	$35

Jun-09-26 02:00AM	PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers (Business Wire) +9.01%
Jun-08-26 07:00AM	Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers (Business Wire)
Jun-01-26 07:00AM	Seaport Therapeutics to Participate in Two Upcoming Investor Conferences (Business Wire) -5.83%

Seaport Therapeutics, Inc. is a clinical-stage therapeutics company, which engages in the provision of inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company was founded on April 1, 2024 and is headquartered in Boston, MA.

Founder & Non-Employee Chair of the BoardDr. Steven M. Paul M.D.

FounderMs. Daphne Zohar

Co-Founder & Chief Scientific OfficerDr. Michael Cunyuan Chen Ph.D.

Chief Medical Officer & President of Clinical DevelopmentDr. Antony Loebel M.D.

Chief Financial OfficerMs. Lauren A. White M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HOMBACH ROBERT J.	Director	Jun 22 '26	Buy	18.14	13,000	235,768	13,000	Jun 24 06:05 AM
ARCH Venture Partners XII, LLC	10% Owner	May 04 '26	Buy	18.00	1,100,000	19,800,000	6,294,951	May 04 06:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

SPTX

Seaport Therapeutics Inc

Upgrade your Finviz experience